Molecular subtyping of “double negative” MIBC. Molecular subtyping of “double negative” MIBC

Identifying patients that benefit from cisplatin-based adjuvant chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC). The purpose of this study is to correlate “luminal” and “basal” type protein expression with histological subtypes, to investigate the prognostic impact on survival after adjuvant chemotherapy and to define molecular subtypes of “double negative” patients (i.e. without expression of CK5/6 or GATA3). Overall design: 10 IHC-double negative cases were analyzed with the HTG transcriptome panel with 19398 mRNA targets. Molecular consensus classification was determined according to Kamoun et al. (Euro Urol, 2019)